Table 3 Correlation of IL-38 serum levels with different demographic, clinical, and laboratory outcomes of the asthmatic groups
From: Serum interleukin 38 (IL-38) as a new potential biomarker of pediatric asthma
Asthmatic patients (n=73) | Atopic patients (n=34) | Non-atopic patients (n=39) | ||||
|---|---|---|---|---|---|---|
R | p | R | p | R | p | |
Age (years) | −0.194 | 0.100 | −0.192 | 0.276 | −0.130 | 0.432 |
Total IgE, (IU/mL) | −0.202 | 0.087 | −0.073 | 0.683 | −0.227 | 0.1640 |
Eosinophils % in PB | −0.354 | 0.003 | −0.575 | <0.001 | −0.143 | 0.386 |
Absolute eosinophils count (cells/ul) | −0.287 | 0.014 | −0.474 | 0.005 | −0.102 | 0.535 |
FEV1 | 0.073 | 0.588 | 0.037 | 0.859 | 0.092 | 0.623 |
FVC | 0.221 | 0.098 | 0.009 | 0.967 | 0.346 | 0.056 |
FEV1/FVC | −0.175 | 0.192 | −0.199 | 0.331 | −.0193 | 0.299 |
ACT | −0.025 | 0.835 | −0.060 | 0.738 | −0.094 | 0.570 |